Dorsey & Whitney Trust CO LLC continued to hold its position in Inogen, Inc (NASDAQ:INGN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,044 shares of the medical technology company’s stock at the close of the second quarter. Dorsey & Whitney Trust CO LLC’s holdings in Inogen were worth $290,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new position in Inogen in the 1st quarter valued at $109,000. Schroder Investment Management Group acquired a new stake in Inogen in the 2nd quarter worth $132,000. Victory Capital Management Inc. grew its position in Inogen by 36.1% in the 1st quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after purchasing an additional 459 shares during the last quarter. Sei Investments Co. grew its position in Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after purchasing an additional 443 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Inogen in the 1st quarter worth $203,000.
ILLEGAL ACTIVITY WARNING: This news story was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.chaffeybreeze.com/2017/09/16/dorsey-whitney-trust-co-llc-has-290000-position-in-inogen-inc-ingn.html.
In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the sale, the director now directly owns 7,808 shares in the company, valued at $715,759.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Matt Scribner sold 2,500 shares of the stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $94.21, for a total transaction of $235,525.00. Following the sale, the executive vice president now owns 4,833 shares in the company, valued at $455,316.93. The disclosure for this sale can be found here. Insiders have sold 44,667 shares of company stock worth $4,170,776 over the last quarter. Corporate insiders own 5.31% of the company’s stock.
Several research firms have issued reports on INGN. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and issued a $90.00 price target on shares of Inogen in a research report on Tuesday. Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Needham & Company LLC restated a “buy” rating and issued a $108.00 price target on shares of Inogen in a research report on Friday, September 1st. Finally, J P Morgan Chase & Co raised their price target on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $91.33.
Inogen, Inc (INGN) opened at 100.87 on Friday. The stock’s 50 day moving average is $95.95 and its 200-day moving average is $87.38. The company has a market capitalization of $2.09 billion, a P/E ratio of 87.56 and a beta of 1.02. Inogen, Inc has a 12-month low of $50.24 and a 12-month high of $104.88.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. The firm had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.25 earnings per share. On average, equities analysts predict that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.